(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number: **0 236 822**
B1

(12) # EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **27.12.90**

(51) Int. Cl.[5]: **A 61 K 31/135**, A 61 K 47/00

(21) Application number: **87102448.5**

(22) Date of filing: **20.02.87**

(54) **Stable injectable pharmaceutical formulation for 1,4-dihydroxy-5,8-bis((2-(hydroxyethylamino)-ethyl)amino)anthraquinone, dihydrochloride.**

(30) Priority: **07.03.86 US 837243**

(43) Date of publication of application:
16.09.87 Bulletin 87/38

(45) Publication of the grant of the patent:
27.12.90 Bulletin 90/52

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI NL SE

(56) References cited:
EP-A-0 003 150
EP-A-0 154 117
US-A-3 230 143
US-A-4 328 213

CHEMICAL ABSTRACTS, vol. 98, no. 6, February 1983, page 355, abstract no. 40504x, Columbus, Ohio, US; C. LIU et al.: "Studies on stability of catecholamine injections and improvement of formulation",

CHEMICAL ABSTRACTS, vol. 102, 1985, page 392, abstract no. 119532q, Columbus, Ohio, US; V. PANDOLFO et al.: "Stability of apomorphine parenteral formulations",

(73) Proprietor: **AMERICAN CYANAMID COMPANY**
1937 West Main Street P.O. Box 60
Stamford Connecticut 06904-0060 (US)

(72) Inventor: **Niphadkar, Pradeep V.**
201 Randolph Avenue
Clifton New Jersey 07011 (US)
Inventor: **Desai, Narendra R.**
Hollcroft Apts. 11H Clapboard Ridge Road
Danbury Connecticut 06810 (US)
Inventor: **Jones, Paul N.**
792 Brookridge Drive
Valley Cottage New York 10989 (US)
Inventor: **Mooney, Kieran G.**
30 Clinton Avenue
Warwick New York 10990 (US)

(74) Representative: **Wächtershäuser, Günter, Dr.**
Tal 29
D-8000 München 2 (DE)

(56) References cited:
CHEMICAL ABSTRACTS, vol. 90, 1979, page 388, abstract no. 210008t, Columbus, Ohio, US; M. STRUHAR et al.: "Studies on the stability and stabilization of aqueous solutions of emetine dichloride",

Courier Press, Leamington Spa, England.

EP 0 236 822 B1

Description

The compound 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride, having the formula:



is described and claimed in U.S. Patent No. 4,197,249 and is sold under the registered trademark Novantrone® in Canada and Europe and is currently under consideration by the United States Food and Drug Administration for approval as an anti-cancer agent.

This compound is known to undergo oxidative degradation in aqueous solution. This degradation occurs much more rapidly in the presence of metal ions such as cuprous, cupric, ferrous and ferric, even when present in minute quantities (e.g. less than 10 ppm).

Since this compound exhibits optimum pharmacological activity in humans when administered parenterally (intramuscularly, intravenously) as opposed to oral administration, it is extremely important that solutions of this compound remain stable for prolonged period under normal storage conditions.

It has now been discovered that the inclusion of a combination of critical factors in an aqueous formulation of 1,4-dihydroxy-5,8-bis[2-(hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride provides a formulation which is extremely stable under normal storage conditions.

These factors are 1) the inclusion of a suitable antioxidant, 2) specific pH range, and 3) the inclusion of a suitable metal ion chelator.

With regard to antioxidants the most effective proved to be sodium metabisulfite.

The most effective pH range was 2.0—3.5 with 3.0 being optimum.

The most effective metal ion chelator was a combination of disodium EDTA and glycine.

Since the desired injectable formulation of 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride contains 1 to 5 mg of this compound per ml of formulation, this new stable formula would have a pH of 2.0 to 3.5, with 3.0 being optimal, a sodium metabilsulfite concentration of 0.01 to 0.10%, with 0.05% being optimal, disodium EDTA at a concentration of 0.01 to 0.11% with 0.10% being optimal, and glycine concentration of 0.05 to 0.2% iwth 0.1% being optimal.

In order to prove the enhanced stability of this new formulation, formulae of the following composition were prepared and stability studies conducted.

Formula I

1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride	2 mg/ml
Water for Injection U.S.P.	100%
Headspace	Air

Formula II

1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride	2 mg/ml
Cupric ions	7 ppm
Water for Injection U.S.P.	100%
Headspace	Air
pH	5.50

Formula III	
1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride	2 mg/ml
Sodium metabilsulfite	0.01%
Sodium acetate	0.005%
Acetic acid, glacial	0.046%
Sodium chloride	0.80%
Water for Injection U.S.P.	100%
pH	3.5
Headspace	Nitrogen

Formula IV	
1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride	2 mg/ml
Sodium metabilsulfite	0.05%
Disodium EDTA	0.10%
Glycine	0.10%
Sodium chloride (Isotonic Agent)	0.786%
Water for Injection U.S.P.	100%
pH	3.0
Headspace	as indicated*

*One portion filled under nitrogen, two portions filled under air.

The results of these stability studies are given below:

Formula	Vial Size	Headspace	Temp.°C	% of Initial Potency					
				1 Day	2 Weeks	3 Weeks	4 Weeks	6 Weeks	8 Weeks
I	10 ml	Air	56		88	84.5		72	
II	10 ml	Air	56	13					
III	10 ml	Nitrogen	56				90		85
III	2 ml	Nitrogen	42				96		93
III	2 ml	Nitrogen	56				85		72
IV	10 ml	Nitrogen	56				99		
IV	2 ml	Nitrogen	42				98.6		97.9
IV	10 ml	Air	56				98		97.6
IV	10 ml	Air	42				98		97.5
V	10 ml	Nitrogen	56				99		98.4

EP 0 236 822 B1

The above results show the superiority of the new formulation of this invention over the previous formulation and an aqueous solution of this drug.

Like most other anticancer drugs, the dose of Novantrone® is based upon the patient's body surface area and disease state. It is highly advantageous from cost and marketing point of view to have Novantrone® product available in small size containers like 2 ml vials. However, because of relatively higher headspace to volume ratio of smaller vials as against the larger vials, the stability of this product becomes critical in small 2 ml vials. It is important to note that the new formulation was found to be superior to the previous formulation in both small as well as relatively larger volume vials.

To further illustrate the stability of this invention a composition was prepared as follows.

Formula V

1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride	2 mg/ml
Disodium EDTA	0.10%
Sodium metabilsulfite	0.04%
Glycine	0.10%
Sodium chloride (Isotonic Agent)	0.60%
Water for Injection U.S.P.	100%
pH	3.0

This formula (V) and a composition of formula (I) each had cupric ions added to a concentration of 6 ppm and were then placed in a stability study at 56°C for 4 weeks. The results at the end of this time showed that formula (I) lost 98% of its potency in 2 days while formula (V) retained 98.6% potency after 4 weeks.

Claims for the Contracting States: BE CH DE FR GB IT LI NL SE

1. A pharmaceutical formulation comprising from 1 to 5 mg per ml of formulation of 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride in an isotonic solution at a pH of from 2.0 to 3.5, containing sodium metabisulfite at a concentration of from 0.01 to 0.10%, disodium EDTA at a concentration of from 0.01 to 0.11% and glycine at a concentration of from 0.05 to 0.20%.

2. A formulation according to Claim 1 where the concentration of 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride is 2 mg/ml and the concentrations of sodium metabisulfite, disodium EDTA and glycine are 0.05%, 0.10% and 0.10% respectively.

Claims for the Contracting States: AT ES GR

1. A method for preparing a pharmaceutical formulation which comprises mixing from 1 to 5 mg per ml of formulation of 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride in an isotonic solution at a pH of from 2.0 to 3.5, containing sodium metabisulfite at a concentration of from 0.01 to 0.10%, disodium EDTA at a concentration of from 0.01 to 0.11% and glycine at a concentration of from 0.05 to 0.20%.

2. A method according to Claim 1, which comprises providing a formulation where the concentration of 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthraquinone, dihydrochloride is 2 mg/ml and the concentrations of sodium metabisulfite, disodium EDTA and glycine are 0.05%, 0.10% and 0.10% respectively.

Patentansprüche für die Vertragsstaaten: BE CH DE FR GB IT LI NL SE

1. Pharmazeutische Formulierung umfassend von 1 bis 5 mg/ml Formulierung an 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthrachinondihydrochlorid in einer isotonischen Lösung bei einem pH von 2,0 bis 3,5, enthaltend Natriummetabilsulfid mit einer Konzentration von 0,01 bis 0,10%, Dinatrium EDTA mit einer Konzentration von 0,01 bis 0,11% und Glycin mit einer Konzentration von 0,05 bis 0,20%.

2. Formulierung gemäß Anspruch 1, wobei die Konzentration an 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthrachinondihydrochlorid 2 mg/ml beträgt und die Konzentrationen von Natriummetabisulfid, Dinatrium EDTA und Glycin 0,05%, 0,10% bzw. 0,10% betragen.

Patentansprüche für die Vertragsstaaten: AT ES GR

1. Verfahren zur Herstellung einer pharmazeutischen Formulierung umfassend das Vermischen von 1 bis 5 mg/ml Formulierung von 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthrachinondihydrochlorid in einer isotonischen Lösung bei einem pH von 2,0 bis 3,5, enthaltend Natriummetabisulfid mit einer Konzentration von 0,01 bis 0,10%, Dinatrium EDTA mit einer Konzentration von 0,01 bis 0,11% und Glycin mit einer Konzentration von 0,05 bis 0,20%.

2. Verfahren gemäß Anspruch 1, wobei man eine Formulierung schafft, bei der die Konzentration an 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthrachinondihydrochlorid 2 mg/ml beträgt und die Konzentrationen von Natriummetabisulfid, Dinatrium EDTA und Glycin 0,05%, 0,10% bzw. 0,10% betragen.

Revendications pour les Etats contractants: BE CH DE FR GB IT LI NL SE

1. Une formulation pharmaceutique comprenant de 1 à 5 mg par ml de formulation de dichlorhydrate de 1,4-dihydroxy-5,8-bis[2-(2-hydroxyéthylamino)éthylamino]anthraquinone dans une solution isotonique à un pH de 2,0 à 3,5, contenant du métabilsulfite de sodium à une concentration de 0,01 à 0,10%, du EDTA disodique à une concentration de 0,01 à 0,11% et de la glycine à une concentration de 0,05 à 0,20%.

2. Une formulation selon la revendication 1, selon laquelle la concentration du dichlorhydrate de 1,4-dihydroxy-5,8-bis[2-(2-hydroxyéthylamino)éthylamino]anthraquinone est de 2 mg/ml et les concentrations de métabisulfite de sodium, de EDTA disodique et de glycine sont de 0,05%, de 0,10% et de 0,10% respectivement.

Revendications pour les Etats contractants: AT ES GR

1. Une méthode de préparation d'une formulation pharmaceutique qui comprend le mélangeage de 1 à 5 mg par ml de formulation de dichlorhydrate de 1,4-dihydroxy-5,8-bis[2-(2-hydroxyéthylamino)éthylamino]anthraquinone, dans une solution isotonique à un pH de 2,0 à 3,5,contenant du métabilsulfite de sodium à une concentration de 0,01 à 0,10%, du EDTA disodique à une concentration de 0,01 à 0,11% et de la glycine à une concentration de 0,05 à 0,20%.

2. Une méthode selon la revendication 1, qui consiste à fournir une formulation dans laquelle la concentration de dichlorhydrate de 1,4-dihydroxy-5,8-bis[2-(2-hydroxyéthylamino)éthylamino]anthraquinone est de 2 mg/ml et les concentrations de métabisulfite de sodium, de EDTA disodique et de glycine sont de 0,05%, de 0,10% et de 0,10% respectivement.

REGISTER ENTRY FOR EP0236822

European Application No EP87102448.5 filing date 20.02.1987

Priority claimed:
07.03.1986 in United States of America - doc: 837243

Designated States BE CH DE ES FR GB GR IT LI NL SE AT

Title STABLE INJECTABLE PHARMACEUTICAL FORMULATION FOR 1,4-DIHYDROXY-5,8-BIS((2-(HYDROXYETHYLAMINO)-ETHYL)AMINO)ANTHRAQUINONE, DIHYDROCHLORIDE

Applicant/Proprietor
AMERICAN CYANAMID COMPANY, 1937 West Main Street P.O. Box 60, Stamford Connecticut 06904-0060, United States of America [ADP No. 500662080031

Inventors
PRADEEP V. NIPHADKAR, 201 Randolph Avenue, Clifton New Jersey 07011, United States of America [ADP No. 55087050001]

NARENDA R. DESAI, Hollcroft Apts. 11H Clapboard Ridge Road, Danbury Connecticut 06810, United States of America [ADP No. 55087068001]

PAUL N. JONES, 792 Brookridge Drive, Valley Cottage New York 10989, United States of America [ADP No. 55087076001]

KIERAN G. MOONEY, 30 Clinton Avenue, Warwick New York 10990, United States of America [ADP No. 55087084001]

Classified to
A5B
A61K

Address for Service
LLOYD WISE TREGEAR & CO, Norman House, 105-109 Strand, London, WC2R 0AE, United Kingdom [ADP No. 00000117001]

EPO Representative
DR. GÜNTER WÄCHTERSHÄUSER, Tal 29, D-8000 München 2, Federal Republic of Germany [ADP No. 50205871001]

Publication No EP0236822 dated 16.09.1987
Publication in English

Examination requested 20.02.1987

Patent Granted with effect from 27.12.1990 (Section 25(1)) with title STABLE INJECTABLE PHARMACEUTICAL FORMULATION FOR 1,4-DIHYDROXY-5,8-BIS((2-(HYDROXYETHYLAMINO)-ETHYL)AMINO)ANTHRAQUINONE, DIHYDROCHLORIDE.

10.01.1989 EPO: Search report published on 11.01.1989
Entry Type 25.11 Staff ID. Auth ID. EPT

29.05.1990 LLOYD WISE TREGEAR & CO, Norman House, 105-109 Strand, London, WC2R
OAE, United Kingdom [ADP No. 000001170011
registered as address for service
Entry Type 8.11 Staff ID. SLP1 Auth ID. AA

**** END OF REGISTER ENTRY ****